Michael Gould to Heparin
This is a "connection" page, showing publications Michael Gould has written about Heparin.
Connection Strength
0.841
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999 May 18; 130(10):789-99.
Score: 0.169
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999 May 18; 130(10):800-9.
Score: 0.169
-
Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials. 2014 Dec 20; 15:502.
Score: 0.125
-
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. JAMA. 2014 Nov 26; 312(20):2135-45.
Score: 0.124
-
Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e227S-e277S.
Score: 0.102
-
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. Curr Opin Pulm Med. 2008 Sep; 14(5):422-6.
Score: 0.081
-
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med. 2007 Jan 08; 167(1):74-80.
Score: 0.072